Fixed-combination therapy to improve blood pressure control: Experience with olmesartan-based therapy

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 7, 2011, Pages 829-840

  Tocci, Giuliano ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

amlodipine besylate; antihypertensive therapy; blood pressure control; calcium channel blocker; fixed combination therapy; hypertension; olmesartan medoxomil; thiazide diuretic

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; OLMESARTAN; PLACEBO; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; HYPERTENSION; IMIDAZOLES; RISK FACTORS; TETRAZOLES;

EID: 79961203301     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.59     Document Type: Review

References (56)

1. Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev. Cardiovasc. Ther. 5(4), 767-776 (2007). (Pubitemid 47053762)
2. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165(12), 1410-1419 (2005). (Pubitemid 40973424)
3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362(9395), 1527-1535 (2003). (Pubitemid 37410190)
4. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336(7653), 1121-1123 (2008). (Pubitemid 351731743)
5. Williams B. The year in hypertension. J. Am. Coll. Cardiol. 55(1), 65-73 (2009).
6. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929-940 (2009).
7. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J. Clin. Hypertens. (Greenwich) 3(4), 211-216 (2001). (Pubitemid 32747167)
8. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43(1), 10-17 (2004). (Pubitemid 38031904)
9. Bramlage P, Bohm M, Volpe M et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J. Clin. Hypertens. (Greenwich) 12(9), 666-677 (2010).
10. Tocci G, Giovannelli F, Sciarretta S, Ferrucci A, Zito GB, Volpe M. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int. J. Clin. Pract. 63(2), 207-216 (2009).
11. Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/ hydrochlorothiazide combination (Diovan/ HCT).Expert Rev. Cardiovasc. Ther. 1(3), 335-343 (2003).
12. Tocci G, Palano F, Pagannone E, Chin D, Ferrucci A, Volpe M. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther. 7(2), 115-123 (2009).
13. Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751-1762 (2007). (Pubitemid 47356612)
14. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121-2158. (2009).
15. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003). (Pubitemid 37553153)
16. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328(7440), 634-640 (2004). (Pubitemid 38340037)
17. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361(9), 878-887 (2009).
18. Angeli F, Verdecchia P, Reboldi GP et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am. J. Hypertens. 17(9), 817-822 (2004). (Pubitemid 39201098)
19. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 21(6), 1055-1076 (2003). (Pubitemid 36667856)
20. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J. Hypertens. 20(8), 1461-1464 (2002). (Pubitemid 34921162)
21. Leonetti G, Cuspidi C, Facchini M. [Antihypertensive therapy in the elderly: results of large trials]. Ital. Heart J. Suppl. 2(11), 1161-1169 (2001). (Pubitemid 34041353)
22. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 288(23), 2981-2997 (2002).
23. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
24. Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin- aldosterone system. J. Am. Soc. Nephrol. 17(4 Suppl. 2), S36-S43 (2006).
25. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 1004-1010 (2002). (Pubitemid 34286537)
26. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005). (Pubitemid 41265663)
27. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
28. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
29. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55(2), 399-407 (2010).
30. Messerli FH, Michalewicz L. Cardiac effects of combination therapy. Am. J. Hypertens. 10(7 Pt 2), 146S-152S (1997).
31. Messerli FH, Grossman E, Michalewicz L. Combination therapy and target organ protection in hypertension and diabetes mellitus. Am. J. Hypertens. 10(9 Pt 2), 198S-201S (1997).
32. Messerli FH. Combination therapy in hypertension. J. Hum. Hypertens. 6(Suppl. 2), S19-S21 (1992). (Pubitemid 23058282)
33. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr. Hypertens. Rep. 9(3), 184-189 (2007). (Pubitemid 46894812)
34. Ruschitzka FT, Noll G, Luscher TF. Combination of ACE inhibitors and calcium antagonists: a logical approach. J. Cardiovasc. Pharmacol. 31(Suppl. 2), S5-S16 (1998). (Pubitemid 128700003)
35. Volpe M, Tocci G. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. J. Nephrol. 20(Suppl. 12), S12-S18 (2007). (Pubitemid 351266132)
36. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with b blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100(8), 1254-1262 (2007). (Pubitemid 47498283)
37. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 62(9), 1345-1353; discussion 1354-1346 (2002).
38. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 68(9), 1239-1272 (2008). (Pubitemid 351822113)
39. Unger T, McInnes GT, Neutel JM, Bohm M. The role of olmesartan medoxomil in the management of hypertension. Drugs 64(24), 2731-2739 (2004). (Pubitemid 40007483)
40. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J. Hypertens. 25(7), 1327-1336 (2007). (Pubitemid 46924066)
41. Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin. Pharmacother. 5(3), 657-667 (2004). (Pubitemid 38344319)
42. Chrysant SG. Amlodipine besylate/ olmesartan medoximil fixed combination for the treatment of hypertension. Expert Rev. Cardiovasc. Ther. 7(8), 887-895 (2009).
43. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertenive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17(3), 252-259 (2004). (Pubitemid 38293331)
44. Barrios V, Boccanelli A, Ewald S et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin. Drug Investig. 27(8), 545-558 (2007). (Pubitemid 47134696)
45. Oparil S, Chrysant SG, Kereiakes D et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J. Clin. Hypertens. (Greenwich) 10(12), 911-921 (2008).
46. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J. Clin. Hypertens. (Greenwich) 9(1), 36-44 (2007).
47. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther. 30(4), 587-604 (2008). (Pubitemid 351680489)
48. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate-to-severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29(1), 11-25 (2009).
49. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29(6), 381-391 (2009).
50. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32(7), 1252-1269 (2010).
51. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J. Clin. Hypertens. (Greenwich) 9(1), 36-44 (2007).
52. Kereiakes DJ, Neutel J, Stoakes KA et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J. Clin. Hypertens. (Greenwich) 11(8), 411-421 (2009).
53. Punzi H, Neutel JM, Kereiakes DJ et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther. Adv. Cardiovasc. Dis. 4(4), 209-221 (2010).
54. Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.[erratum appears in J. Clin. Hypertens. (Greenwich) 2004 Jun; 6(6): 346]. J. Clin. Hypertens. (Greenwich) 6(4), 168-174 (2004).
55. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J. Hypertens. 23(11), 2083-2092 (2005). (Pubitemid 41830405)
56. Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J, Shojaee A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and Type 2 diabetes. Curr. Med. Res. Opin. 26(3), 721-728 (2010).